格隆汇9月2日丨君实生物(01877.HK)公告，于2025年9月2日，董事会已审议及批准(其中包括)(i)建议采 纳2025年H股股票期权激励计划；及(ii)采纳2025年A股股票期权激励计划。根据上市规则第十七章， 2025年H股股票期权激励计划及2025年A股股票期权激励计划将构成公司涉及发行新股份的股份计划， 因此采纳2025年H股股票期权激励计划及2025年A股股票期权激励计划须获股东批准。 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-046 上海君实生物医药科技股份有限公司 第四届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 上海君实生物医药科技股份有限公司（以下简称"公司"）第四届董事会第 十一次会议于2025年9月2日以现场及通讯表决的方式在公司会议室召开。会议由 董事长熊俊先生主持，应出席董事14名，实际出席董事14名。本次会议的召集、 召开程序符合《中华人民共和国公司法》（以下简称"《公司法》"）及《上海 君实生物医药科技股份有限公司章程》（以下简称"《公司章程》"）的相关规 定，会议决议合法、有效。 二、董事会会议审议情况 （以下简称"《管理办法》"）、 《上海证券交易所科创板 股票上市规则》（以下简称"《科创板上市规则》"）《科创板上市公司自律监管指 南第 4 号——股权激励信息披露》 （以下简称"《自律监管指南第 4 号》"）等有关 法律、行政法规、规范性文件以及《公司章程》的规定，公司制定了《上海君实 生物医药科技股 ...

上海君实生物医药科技股份有限公司监事会 关于《公司 2025 年 A 股股票期权激励计划（草案）》的 核查意见 上海君实生物医药科技股份有限公司（以下简称"公司"）监事会依据《中 华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称" 《证券法》"）、 《上市公司股权激励管理办法》 （以下简称"《管理办法》"）、 《上海证券交易所科创板股票上市规则》 （以下简称"《上市规则》"）、 《科创板上 市公司自律监管指南第 4 号——股权激励信息披露》等相关法律、法规及规范性 文件和《上海君实生物医药科技股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，对《上海君实生物医药科技股份有限公司 2025 年 A 股股票期权激 励计划（草案）》 （以下简称"《激励计划（草案）》"或"本次激励计划"）进行了 核查，发表核查意见如下： 一、公司不存在《管理办法》规定的不得实行股权激励的以下情形： 公司具备实施股权激励计划的主体资格。 二、本次激励计划所确定的激励对象具备《公司法》《证券法》《上市规则》 等法律、法规和规范性文件及《公司章程》规定的任职资格，且不存在下列情形： （一）最近 ...

证券代码：688180 证券简称：君实生物 公告编号：临 2025-045 上海君实生物医药科技股份有限公司 第四届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海君实生物医药科技股份有限公司（以下简称"公司"）第四届监事会第 九次会议于2025年9月2日以通讯的方式召开。本次会议由监事会主席匡洪燕女士 主持，会议应到监事3人，实到监事3人。会议的召集和召开程序符合《中华人民 共和国公司法》（以下简称"《公司法》"）和《上海君实生物医药科技股份有 限公司章程》（以下简称"《公司章程》"）的规定，会议形成的决议合法、有 效。 二、监事会会议审议情况 （一）审议通过《关于 <公司2025年a股股票期权激励计划 草案="草案"> 及其摘 要及建议向一名董事兼主要股东授予A股股票期权的议案》 经审核，公司监事会认为《公司2025年A股股票期权激励计划（草案）》及 其摘要的内容符合《公司法》 《中华人民共和国证券法》 （以下简称"《证券法》"）、 《上市公司股权激励管理办法》 （ ...

上海君实生物医药科技股份有限公司 2025 年 A 股股票期权激励计划实施考核管理办法 第三条 考核范围 上海君实生物医药科技股份有限公司 实施考核管理办法 上海君实生物医药科技股份有限公司（以下简称"公司"或"君实生物"） 为了进一步建立、健全公司长效激励机制，吸引和留住优秀人才，充分调动公司 （含子公司）的员工积极性，有效地将股东利益、公司利益和核心团队个人利益 结合在一起，使各方共同关注公司的长远发展，在充分保障股东利益的前提下， 按照收益与贡献对等的原则，公司制订了《上海君实生物医药科技股份有限公司 为保证公司 2025 年 A 股股票期权激励计划（以下简称"本激励计划"）的顺 利实施，现根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公 司股权激励管理办法》《上海证券交易所科创板股票上市规则》《科创板上市公 司自律监管指南第 4 号——股权激励信息披露》等有关法律、行政法规、规范性 文件和《公司章程》的有关规定，并结合公司实际情况，特制订本办法。 第一条 考核目的 制定本办法的目的是加强本激励计划执行的计划性，量化本激励计划设定的 具体目标，促进激励对象考核管理的科学化、规范化、制度化，确 ...

上海君实生物医药科技股份有限公司 2025 年 A 股股票期权激励计划（草案） 证券简称：君实生物 证券代码：688180 上海君实生物医药科技股份有限公司 （草案） 二〇二五年九月 上海君实生物医药科技股份有限公司 2025 年 A 股股票期权激励计划（草案） 声 明 本公司董事会及全体董事保证本激励计划及其摘要不存在虚假记载、误导性 陈述或重大遗漏，并对其真实性、准确性、完整性依法承担法律责任。 预留激励对象指本激励计划获得股东大会批准时尚未确定但在本激励计划 存续期间纳入本激励计划的激励对象，应当在本激励计划经股东大会审议通过后 会认为需要激励的其他人员，不包括公司独立董事、监事、单独或合计持有公司 上海君实生物医药科技股份有限公司 2025 年 A 股股票期权激励计划（草案） 本激励计划的激励对象符合《上市公司股权激励管理办法》第八条的规定， 不存在不得成为激励对象的下列情形： （三）最近12个月内因重大违法违规行为被中国证监会及其派出机构行政处 罚或者采取市场禁入措施； （四）具有《公司法》规定的不得担任公司董事、高级管理人员情形的； 本公司所有激励对象承诺，若公司因信息披露文件中有虚假记载、误导性 ...

Core Viewpoint - The supervisory board of Hengsheng Electronics Co., Ltd. has verified and publicly announced the list of incentive recipients for the 2025 stock option incentive plan, ensuring compliance with relevant regulations and internal procedures [1][3]. Summary by Sections Incentive Recipient List Announcement - The company has conducted an internal public announcement regarding the names and positions of the proposed incentive recipients as part of the 2025 stock option incentive plan [1]. - Feedback was collected from the supervisory board regarding the public announcement, and any objections raised were recorded [1]. Supervisory Board Verification - The supervisory board has reviewed the proposed list of incentive recipients, their identification documents, employment contracts, and their positions within the company [3]. - The verification process ensures that all proposed recipients meet the conditions set forth by relevant laws and regulations, including not being classified as inappropriate candidates by the securities exchange or the China Securities Regulatory Commission (CSRC) within the last 12 months [3]. Supervisory Board's Review Opinion - The supervisory board concluded that all individuals included in the incentive plan are legally and effectively qualified as incentive recipients under the applicable laws and regulations [3].

Core Viewpoint - The announcement details the implementation of the stock option incentive plan for 2023, specifically the second exercise period, which allows eligible participants to exercise a total of 55,053,109 stock options at a price of 17.97 yuan per share, representing 1.57% of the company's total share capital [1][9][10]. Summary by Sections Stock Option Plan Details - The second exercise period for the stock options is set from August 28, 2025, to August 27, 2026, with actual exercise dates from September 3, 2025, to August 27, 2026 [1][9]. - A total of 4,735 participants are eligible to exercise the stock options during this period [1][6]. Approval Process - The stock option incentive plan underwent several approval processes, including reviews by the board of directors and the supervisory board, with independent legal opinions provided [1][3][4]. - Adjustments were made to the number of participants and the total stock options granted, reducing the initial number from 5,704 to 5,551 participants and from 210 million to 208.9909 million stock options [1][4][8]. Performance Conditions - The performance conditions for the stock options include achieving specific financial metrics, such as revenue targets of at least 106.382 billion yuan for 2024 and 129.848 billion yuan for 2025, with a required growth rate of 100% and 140% respectively [6][7]. - The evaluation of individual performance will determine the percentage of options that can be exercised, with different tiers based on performance ratings [6][7]. Financial Impact - If all options are exercised, the company's net assets will increase by approximately 989.3044 million yuan, with a total share capital increase of 55,053,109 shares [9][10]. - The exercise of stock options is not expected to have a significant impact on the company's financial results for the year [9]. Management of Funds - Funds raised from the exercise of stock options will be used to supplement the company's working capital, and participants are responsible for paying personal income tax on their gains [10][11]. Future Reporting - The company will disclose changes in the stock option incentive plan, adjustments to key parameters, and the status of participant exercises in regular and interim reports [12].

Group 1 - The company announced the completion of the cancellation of stock options under the 2021 stock option incentive plan due to unmet performance conditions for the third exercise period [1][2] - A total of 5,771,200 stock options were canceled, including 5,658,800 options for those who did not meet the exercise conditions and 112,400 options for individuals who resigned [2] - After the cancellation, there are no remaining stock options for the incentive plan, and the number of eligible incentive recipients is zero [2][3] Group 2 - The cancellation process was confirmed by the China Securities Depository and Clearing Corporation Limited on September 2, 2025 [3] - The cancellation aligns with the regulations of the incentive plan and does not affect the company's capital structure or operational status [3] - The management team will continue to fulfill their responsibilities and strive to create value for shareholders following the completion of this incentive plan [3]

Group 1 - The company reported overseas sales of 45,166 units in August 2025, with cumulative sales of 283,912 units from January to August 2025 [3] - In August 2025, the company sold 37,495 units of new energy vehicles, totaling 232,502 units sold from January to August 2025 [4] Group 2 - During the period from August 1 to August 31, 2025, a total of 1,000 yuan of "Changqi Convertible Bonds" were converted into 25 shares of company stock [7] - From December 17, 2021, to August 31, 2025, a total of 4,900,000 yuan of "Changqi Convertible Bonds" were converted into 128,529 shares, representing 0.0014% of the company's total issued shares before conversion [10] - As of August 31, 2025, the amount of unconverted convertible bonds was 3,495,099,000 yuan, accounting for 99.86% of the total issuance [11] Group 3 - The first exercise period of the 2023 stock option incentive plan allowed for 18,948,783 shares to be exercised, with no shares exercised in August 2025 [8][19] - The exercise price for the first exercise period of the 2023 stock option incentive plan was adjusted to 26.47 yuan per share [18] - As of August 31, 2025, a total of 30 shares were exercised under the 2023 stock option incentive plan, raising 807.60 yuan for working capital [22]